Should I buy Incyte (INCY) stock or is it too late?

Incyte · Health Care · price $109

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (240 calls tested). It aims for $130 (+20 %), call made on July 30, 2026, maturing on July 30, 2027 (76 d ago).

The 12 reliable analysts $138+27 %

The 5 other firms $105-3.3 %

How to read it: the 12 reliable firms are not filtered by optimism — 11 aim above the price, 1 below, hence their $138 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Incyte

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Jefferies	71 %	+59.1 %	7	$94 -13%
Barclays	67 %	+22.9 %	6	$139 +28%
Oppenheimer	67 %	+16.3 %	12	$90 -17%
Truist Securities	67 %	+10.8 %	6	$105 -3%
RBC Capital	50 %	+1.1 %	6	$114 +5%
Morgan Stanley	67 %	-15.8 %	6	$104 -4%
BMO Capital	14 %	-21.9 %	7	$130 +20%
B of A Securities	62 %	+35.7 %	8	—

In short — Should you invest in Incyte? Is it too late, still worth it? Analysts are split (47% buy, median target $130, i.e. +20%), and the most reliable on INCY targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $130, i.e. +20% from the current price ($109).
The most reliable firm on INCY, Stifel (100% hit rate, 2 scored calls), targets $157 (call made on October 5, 2026, maturing on October 5, 2027) (+45%) in its most recent call, and $120 (call made on February 11, 2026, maturing on February 11, 2027) (+10%) in the one coming due soonest.
8 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
Reasonable valuation (P/E ~14) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 17 ratings, 9 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on INCY

Median target $130 (+20%) · 17 ratings · Hold consensus

Strong Buy00%

Buy847%

Hold953%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Incyte now?

We won't decide for you. The facts: 47% of analysts rate it a buy, median target $130 (+20%), and Stifel (most reliable on INCY, 100%) targets $157. Weigh that against valuation (P/E ~14). This is not personalized advice.

Is it too late to invest in Incyte?

Not according to analysts: the median target ($130) is still +20% above the current price ($109) (most reliable on INCY: Stifel, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Incyte still worth investing in?

It depends on the gap between the price ($109) and its estimated value: analysts target $130 on median (+20%), with 47% buys (most reliable on INCY: Stifel, 100%). Cross-check with their real reliability on INCY and the cautions above. Information, not advice.

What's the main risk in buying INCY?

The consensus is not unanimous: of 17 ratings, 9 are neutral.

→ Go deeper: the full Incyte profile (consensus, analyst reliability, price target, performance).